Provention Bio, Inc. Common Stock
PRVB
PRVB was delisted on the 26th of April, 2023.
106 hedge funds and large institutions have $378M invested in Provention Bio, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 35 reducing their positions, and 10 closing their positions.
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
33% more capital invested
Capital invested by funds: $284M → $378M (+$94M)
6% more funds holding
Funds holding: 100 → 106 (+6)
3% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 35
53% less call options, than puts
Call options by funds: $1.11M | Put options by funds: $2.35M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.16M |
| 2 |
Morgan Stanley
New York
|
+$3.12M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$3.12M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.27M |
| 5 |
Squarepoint
New York
|
+$1.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JJIJ
Johnson & Johnson Innovation - JJDC
New Brunswick,
New Jersey
|
-$7.38M |
| 2 |
Two Sigma Investments
New York
|
-$2.42M |
| 3 |
SG Americas Securities
New York
|
-$2.02M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$1.04M |
| 5 |
Goldman Sachs
New York
|
-$913K |
PRVB Hedge Fund Activity: Q4 2020 in Review
106 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q4 2020, worth a combined $378M — up 33% from $284M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new PRVB positions and 10 closed out — a net gain of 7 holders — while 34 added to existing stakes and 35 trimmed.
The largest buyer was BlackRock, adding an estimated $9.16M. The largest seller was Johnson & Johnson Innovation - JJDC, exiting entirely with an estimated $7.38M sold.
- 106 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q4 2020, up from 100 in Q3 2020.
- Funds reported $378M of Provention Bio, Inc. Common Stock stock for Q4 2020, up 33% quarter-over-quarter.
- 17 funds opened new Provention Bio, Inc. Common Stock positions in Q4 2020 and 10 closed out, a net change of +7 holders.
- The largest Provention Bio, Inc. Common Stock buyer in Q4 2020 was BlackRock, an estimated $9.16M added.
- The largest Provention Bio, Inc. Common Stock seller in Q4 2020 was Johnson & Johnson Innovation - JJDC, an estimated $7.38M sold.
Based on aggregated 13F filings for Q4 2020.